AMENDMENT TO THE CLAIMS

1-36. (Canceled)

37. (Currently Amended) A method for reducing tissue factor levels to treat cancer comprising administering to ~~the~~ a mammal a therapeutically effective amount of an antibody or fragment thereof ~~capable of binding~~ that binds native human tissue factor to form a complex, whereby Factor X binding to the complex is inhibited and Factor VII or VIIa binding to tissue factor is not inhibited, ~~wherein the method further comprises contacting cancer cells expressing TF with the antibody or fragment to reduce the tissue factor levels in the mammal to treat the cancer.~~.

38. (Canceled)

39. (Currently Amended) The method of claim 37, wherein the antibody or fragment has the binding specificity for native human tissue factor about equal to or greater than H36.D2.B7 deposited as [ATCC HB12255].

40. (Currently Amended) The method of claim ~~38~~37, wherein the antibody has identifying characteristics of H36.D2.B7 deposited as [ATCC HB-12255].

41. (Currently Amended) The method of claim ~~40~~ 37, wherein the antibody is H36.D2.B7 deposited as [ATCC HB- 12255].

42. (Previously Presented) The method of claim 37, wherein the antibody is a monoclonal antibody.

43. (Currently Amended) The method of claim ~~42~~ 37, wherein the antibody is chimeric ~~or humanized~~.

44. (Currently Amended) The method of claim ~~43~~ 65, wherein the chimeric antibody ~~is chimeric and~~ further comprises a constant region of human origin.

45. (Currently Amended) The method of claim ~~43~~ 66, wherein the humanized antibody comprises hypervariable regions of non-human origin.

46. (Previously Presented) The method of claim 37, wherein the antibody is a single chain antibody.

47. (Canceled)

48. (Previously Presented) The method of claim 47, wherein the antibody comprises a sequence represented by SEQ ID NO:4.

49-53. (Canceled)

54. (Currently Amended) The method of claim ~~53~~ 37, wherein the fragment is a Fab, F(v), Fab', or ~~F(ab)2~~ $F(ab')_2$ fragment.

55. (Currently Amended) The method of claim 37, wherein the Factor X ~~FX or FVII/FVIIa~~ binding to the complex is inhibited by at least 80 percent in a standard in vitro binding assay.

56. (Currently Amended) The method of claim 37, wherein the Factor X ~~FX or FVII/FVIIa~~ binding to the complex is inhibited by at least 90 percent in a standard in vitro binding assay.

57. (Currently Amended) The method of claim 37, wherein the Factor X ~~FX or FVII/FVIIa~~ binding to the complex is inhibited by at least 95 percent in a standard in vitro binding assay.

58. (Previously Presented) The method of claim 37, wherein administration of the antibody increases the clotting time by at least 90 percent according to a prothrombin time (PT) assay.

59. (Previously Presented) The method of claim 37, wherein administration of the antibody increases the clotting time by at least 150 percent according to a prothrombin time (PT) assay.

60. (Previously Presented) The method of claim 37, wherein administration of the antibody increases the clotting time by at least 300 percent according to a prothrombin time (PT) assay.

61. (Currently Amended) The method of claim 37, wherein the cancer ~~cell~~ is a pancreatic cancer, ovarian cancer, colorectal cancer, bladder cancer, breast cancer, melanoma, or small lung cell carcinoma.

62. (Withdrawn) A method for detecting cancer cells that express TF, the method comprising contacting cancer cells expressing TF with a detectably-labeled antibody capable of

binding native human tissue factor to form an immune complex; and detecting the immune complex as being indicative of the cancer cells that express the TF.

63. (Withdrawn) The method of claim 62, wherein the method further comprises administering an effective amount of the antibody to a mammal and detecting the cancer cells that express the TF in the mammal.

64. (Withdrawn) The method of claim 62, wherein the method further comprises isolating a biological sample from the mammal and detecting the cancer cells that express TF in the sample.

65. (New) The method of claim 43, wherein the chimeric antibody comprises a mouse variable region.

66. (New) The method of claim 37, wherein the antibody is a human or humanized antibody.

67. (New) The method of claim 37, wherein the antibody fragment is derived from a humanized or chimeric antibody.

68. (New) The method of claim 37, wherein the antibody variable regions are encoded by SEQ ID NO: 1 or SEQ ID NO: 3.